207 related articles for article (PubMed ID: 30964552)
1. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
[TBL] [Abstract][Full Text] [Related]
2. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
[TBL] [Abstract][Full Text] [Related]
3. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
4.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
5. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
[TBL] [Abstract][Full Text] [Related]
6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
7. Expert opinion on the management of renal manifestations of chronic HCV infection.
Fabrizi F; Negro F; Bondin M; Cacoub P
Antivir Ther; 2018; 23(Suppl 2):57-67. PubMed ID: 30451153
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
[TBL] [Abstract][Full Text] [Related]
9. Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Pisaturo M; Starace M; Minichini C; De Pascalis S; Occhiello L; Fraia AD; Messina V; Sangiovanni V; Claar E; Coppola N;
Int J Antimicrob Agents; 2020 Sep; 56(3):106067. PubMed ID: 32599227
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P
Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897
[TBL] [Abstract][Full Text] [Related]
11. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
12. HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Minichini C; Starace M; De Pascalis S; Macera M; Occhiello L; Caroprese M; Vitrone M; Iovinella V; Guerrera B; Masarone M; Coppola N
Antivir Ther; 2018; 23(7):605-609. PubMed ID: 29504510
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
[TBL] [Abstract][Full Text] [Related]
15. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
[TBL] [Abstract][Full Text] [Related]
16. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
de Salazar A; Dietz J; di Maio VC; Vermehren J; Paolucci S; Müllhaupt B; Coppola N; Cabezas J; Stauber RE; Puoti M; Arenas Ruiz Tapiador JI; Graf C; Aragri M; Jimenez M; Callegaro A; Pascasio Acevedo JM; Macias Rodriguez MA; Rosales Zabal JM; Micheli V; Garcia Del Toro M; Téllez F; García F; Sarrazin C; Ceccherini-Silberstein F;
J Antimicrob Chemother; 2020 Nov; 75(11):3349-3358. PubMed ID: 32772078
[TBL] [Abstract][Full Text] [Related]
19. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
[TBL] [Abstract][Full Text] [Related]
20. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
Hubbard H; Lawitz E
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]